A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)

Administered By

Awarded By

Contributors

Start/End

  • September 30, 2019 - October 14, 2024